SMACC

SMACC aggregates chemogenomics data from ChEMBL to compile a curated collection of small-molecule antiviral compounds for discovery and development of broad-spectrum antiviral agents against 13 high-priority emerging viruses.

Key Features:

• Extensive Data Integration: Consolidates over 32,500 compound entries with data from phenotypic and target-based assays for the selected viruses.
• Highly Curated Database: Applies rigorous curation and annotation to address data annotation accuracy and ensure high-quality chemogenomics records.
• Identification of Polyviral Inhibitors: Includes results from detailed analyses identifying approximately 50 compounds with polyviral inhibition profiles, notably active against flavi- and coronaviruses.
• Support for Broad-Spectrum Antiviral (BSA) Development: Provides a reference dataset to aid identification and optimization of novel broad-spectrum antiviral agents.

Scientific Applications:

• Exploring Compound Efficacy: Enables investigation of compound activity across multiple viruses using integrated phenotypic and target-based assay data.
• Facilitating Drug Repurposing: Supports identification of existing drugs with antiviral activity for potential repurposing against the included emerging viruses.
• Supporting Comparative Analyses: Promotes cross-virus comparative analyses to inform discovery and optimization of broad-spectrum antiviral strategies.

Methodology:

Integration of chemogenomics data from ChEMBL; rigorous curation and annotation to correct data annotation issues; integration of phenotypic and target-based assay data; analysis of the integrated dataset to identify polyviral inhibitors.